Shares of DiaMedica Therapeutics Inc. (DMAC) touched a 52-week high of $6.41 last week, driven by investor optimism following the recent key updates on its clinical pipeline, including the ReMEDy2 trial for acute ischemic stroke and the Phase 2 preeclampsia study.
The clinical-stage biopharmaceutical company is advancing its lead candidate, DM199, a recombinant form of human tissue kallikrein-1 (rhKLK1), in trials for both acute ischemic stroke and preeclampsia.
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.